Axsome Therapeutics, Inc. Earnings

Axsome Therapeutics, Inc.’s revenue jumped 61.95% since last year same period to $121.46Mn in the Q1 2025. On a quarterly growth basis, Axsome Therapeutics, Inc. has generated 2.27% jump in its revenue since last 3-months.

Axsome Therapeutics, Inc.’s net profit jumped 13.08% since last year same period to $-59.41Mn in the Q1 2025. On a quarterly growth basis, Axsome Therapeutics, Inc. has generated 20.69% jump in its net profits since last 3-months.

Axsome Therapeutics, Inc.’s net profit margin jumped 46.33% since last year same period to -48.91% in the Q1 2025. On a quarterly growth basis, Axsome Therapeutics, Inc. has generated 22.45% jump in its net profit margins since last 3-months.

Axsome Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.21 - a -20.69% fall from last quarter’s estimates.

Axsome Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -1.21.

Axsome Therapeutics, Inc.’s earning per share (EPS) jumped 15.58% since last year same period to -1.22 in the Q1 2025. This indicates that the Axsome Therapeutics, Inc. has generated 15.58% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Axsome Therapeutics, Inc.’s return on assets (ROA) stands at -0.26.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Axsome Therapeutics, Inc.’s return on equity (ROE) stands at -2.82.